Clinical trials / NCT03870620
Recruiting

Metastatic Breast Cancer in Austria

Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive tumours metastasise at a later date. Metastatic breast cancer has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus…

ClinicalTrials.gov IDNCT03870620
PhaseNot Applicable
Enrollment5000
SponsorArbeitsgemeinschaft medikamentoese Tumortherapie
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Breast Cancer, Breast Carcinoma, Breast Tumor

About this study

Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive tumours metastasise at a later date. Metastatic breast cancer has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardised documentation of this disease. The aim of the registry is to answer both epidemiological and therapy-specific questions. This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria. All tumour characteristics, medical histories and also treatment sequences are documented in anonymised form.

Primary outcomes

Eligibility information

Inclusion Criteria: * Histological evidence of breast cancer * Histological and/or radiological evidence of metastases * Metastasis within 10 years of registry initiation * Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent) Exclusion Criteria: * Due to the non-interventional design of the registry there are no specific exclusion criteria.

Study locations

Showing 10 of 16 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.